by Alpha | Oct 28, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
2. ALXN:$ALXN upgraded from Underperform to Mkt Perform at FBR. PT $130
3. COP:$COP upgraded to Overweight at PiperJaffray
8. TWTR:$TWTR maintains Buy rating at Goldman Sachs – PT cut $22 from $23, upgraded to Perform at Oppenheimer
DOWNGRADES
2. BIDU:$BIDU downgrades to Neutral at Credit Suisse – PT cut $173 from $184
5. EA:$EA downgraded to Market Perform at Cowen & Co
EARNINGS
Trending Social Alerts
1. XOM:$XOM Exxon Mobil Q3 16 Earnings Results: -Adj EPS: $0.63 -Revenue: $58.68B
6. MA:Mastercard Reports Q3 EPS $1.08 vs $0.98 Est., Sales $2.9B vs $2.75B Est. $MA
7. OPXA:$OPXA halted news pending
Trending News Headlines
1. General Electric Pursues Deal With Baker Hughes
GGeneral Electric is in talks to merge its oil-and-gas business with Baker Hughes, according to people familiar with the matter, a transaction that would dramatically reshape the industrial giant.
2. Apple Has Raised Computer Prices by 20% Because of Brexit
Apple Inc. quietly raised the cost of some of its products in Britain by 20 percent, the latest blow to U.K. consumers after the decision to leave the European Union sent the pound sliding.
3. j l on Twitter
“$CEMP manufacturing woes as detailed in the 10Q”
Technology News
by Alpha | Oct 26, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
3. PRTO:$PRTO upgraded to Strong Buy from Outperform at Raymond James. PT $19
4. TWX:$TWX upgraded to Overweight at Barclays – PT raise $95 from $74
DOWNGRADES
1. CMG:$CMG downgraded to Neutral at Credit Suisse – PT cut $375 from $500
3. GM:$GM downgraded to Neutral at Bank of America
5. P:$P downgraded to Underweight at Albert Fried – PT cut $8 from $16
6. RIG:$RIG downgraded to Underweight at Morgan Stanley
7. T:$T downgraded to Equal-Weight at Barclay
EARNINGS
Trending Social Alerts
1. BIIB:$BIIB Q3 Tecfidera sales $1.03B, slight beat but helped by $40-50M inventory build.
2. LUV:Southwest Airlines Q3 EPS $0.93 vs $0.88 est, Revenue $5.14B vs $5.17B est. $LUV
3. CMCSA:EARNINGS ALERT: Comcast EPS beats $0.92 vs. $0.91 • revs. beat $21.319B vs. $21.165B $CMCSA
4. BA:Boeing Q3 EPS $3.51 vs $2.62 est, Revenue $23.9B vs $23.6B est. $BA
5. KO:Coca Cola Q3 EPS $0.49 vs $0.48 est, Revenue $10.63B vs $10.51B est. $KO
6. SIX:$SIX results look pretty dismal after 7,000 Nov. $50 puts bought yesterday into the report
8. NERV:$NERV Announces Positive Data From Six-Month Extension of Phase IIb Trial of MIN-101 Monotherapy in Schizophrenia
10. VRTX:Why is $VRTX incapable of providing investors with unambiguously good news? There’s always drama, something to worry about.
12. PNRA:$PNRA :”Trade Idea 1: Buy the November 195/190-185 1×2 Put Spread for a $1 credit.” keep the credit, can BTC 185 to release margin
Trending News Headlines
1. Here’s How Goldman Sachs Fires People
The first “plant layoff” notice came in February: 43 people would lose their jobs.
2. Biogen profit beats estimates on sales of MS drug
By
3. U.S. warned Berlin on China-Aixtron deal: Handelsblatt
U.S. intelligence services warned Berlin that a now on-hold Chinese takeover of German semiconductor equipment maker Aixtron (AIXGn.DE) could give Beijing access to technology that could be used for military purposes, business daily Handelsblatt said.
4. Comcast Reports Strong Earnings, Powered by Rio Olympics
Comcast Corp. reported better-than-expected financial results and added video customers in the third quarter, as its NBCUniversal business saw strong growth powered by the Rio Olympics.
Technology News
If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
by Alpha | Oct 25, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
3. CHK:$CHK upgraded to Sector Perform at RBC Capital
DOWNGRADES
1. ARIA:$ARIA downgraded to Market Perform at JMP Securities.
8. V:$V downgraded to Neutral at Guggenheim, maintains Buy rating at UBS – PT raise $97 from $90
9. VFC:$VFC downgraded to Hold at Deutsche Bank – PT raise $97 from $90, maintains Buy rating at UBS – PT cut $59 from $65
EARNINGS
Trending Social Alerts
1. MRK:$MRK Merck & Co Q3 16 Earnings Results: -Adj EPS: $1.07 -Revenue: $10.5B
2. UA:Under Armour Reports Q3 EPS $0.29 vs $0.25 Est., Sales $1.472B vs $1.45B Est. $UA
6. UTX:$UTX United Technologies Q3 16 Earnings Results: -Adj EPS: $1.76 -Revenue: $14.4B
9. NVS:Strong indication from Jimenez on conf call that $NVS would love to sell Roche stake to buy bolt-on instead – actively looking
11. DD:#jimcramer $DD raises 2016 operating profit guidance – my RealMoneyPro long standing favorite large cap for 2016
13. DPRX:$DPRX halt
14. PG:P&G Reports Q1 Adj. EPS $1.03 vs $0.98 Est., Sales $16.52B vs $16.5B Est. $PG
15. MMM:$GM crushes numbers, “Automotive Strength” a theme across multiple industry reports including $MMM and $DD today
Trending News Headlines
1. Bear thesis on Corbus Pharma could cause a crash landing for high-flying biotech stock
The market is acting like resunab is a real drug, which is why my investor source is short Corbus.
2. Twitter Planning Hundreds More Job Cuts as Soon as This Week
Twitter Inc. is planning widespread job cuts, to be announced as soon as this week, according to people familiar with the matter.
3. Caterpillar Lowers Sales Forecast as Rebound Proves Elusive
Caterpillar Inc., the biggest maker of construction and mining equipment, cut its 2016 revenue forecast and said next year won’t be much different as companies defer purchases amid sluggish growth and low commodity price expectations. Shares fell.
4. Merck Announces Third-Quarter 2016 Financial Results | Merck Newsroom Home
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2016.
5. Under Armour Tumbles After Forecast Renews Fears of Slowdown
Under Armour Inc. shares fell as much as 18 percent in early trading after its long-term forecast renewed fears that the athletic brand’s growth streak is finally sputtering.
6. New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin Lymphoma Patients | Business Wire
New Results Presented for Opdivo (nivolumab) Demonstrate Encouraging Response Rate in an Expanded Population of Heavily Pre-Treated Classical Hodgkin
7. Pfizer cuts price of Enbrel to match rival ‘biosimilar’ drug
Price drop is first under pricing deal signed by Government and Irish Pharmaceutical Healthcare Association
8. Syngenta-ChemChina Deal Closing Likely to Be Delayed
Swiss seed and pesticide maker Syngenta said regulatory approval of its proposed acquisition by ChemChina is likely to be delayed into early 2017 as regulators seek more information amid a consolidation wave in the sector.
9. Baker Hughes posts smaller-than-expected loss as cost cuts pay off
Oilfield services provider Baker Hughes Inc (BHI.N) reported a much smaller-than-expected quarterly loss as the company’s aggressive cost-cutting measures paid off.
10. Sheff on Twitter
“$TGTX..$6.23..Key Milestones & $15 PT valuation (Sun)”
11. UPDATE: Chardan Capital Markets Starts Clovis Oncology (CLVS) at ‘Sell’ With Price Target of $15
(Updated – October 25, 2016 8:28 AM EDT) Chardan Capital Markets initiated coverage on Clovis Oncology (NASDAQ: CLVS) with a Sell rating and a price target of $15. Analyst Madhu Kumar doesn’t…
12. Uber’s Otto hauls Budweiser across Colorado in self-driving truck
In the first real-world commercial use of autonomous trucking, some 45,000 cans of Budweiser beer arrived late last week to a warehouse after traveling over 120 highway miles in a self-driving truck with no driver at the wheel, executives from Uber [UBER.UL] and Anheuser-Busch (ABI.BR) said.
13. Goldman, closer to Murdoch than Bugs Bunny, misses year’s biggest deal
It has been six years since Goldman Sachs Group Inc, a perennial No. 1 in the M&A league tables, did not feature as an adviser on the year’s biggest deal. But sticking with Rupert Murdoch over Bugs Bunny just cost it this year’s biggest deal.
Technology News
Meanwhile in Europ
The European banks are in much worse shape than their US competition. The reason being argued in Europe is that the US government imposed a ban on speculation
Today’s Economic Calendar
8:55 Redbook Chain Store Sales
9:00 FHFA House Price Index
9:00 S&P Case-Shiller Home Price Index
10:00 Consumer Confidence
10:00 Richmond Fed Mfg.
10:00 State Street Investor Confidence Index
1:00 PM Results of $26B, 2-Year Note Auction
1:20 PM Fed’s Lockhart speech
If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
by Alpha | Oct 24, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
3. CHK:WOW another $CHK UPGRADE!!! DJ Chesapeake Energy Raised to Equal-Weight From Underweight by Stephens & Co. Mon Oct 24 08:36:10 2016
4. DKS:$DKS upgraded to Outperform at Cowen & Co
9. KMI:$KMI upgraded to Outperform at BMO Capital
12. WYNN:$WYNN upgraded to Overweight by Morgan Stanley
DOWNGRADES
1. ADAP:$ADAP downgraded to Underperform from Neutral at BofA.
4. EA:$EA downgraded to Neutral at Bank of America
7. T:$T downagraded to Market Perform at Cowen & Co, downgraded to Hold at Drexel Hamilton
8. TEVA:$TEVA downgraded to Neutral at Mizuho
EARNINGS
Trending Social Alerts
1. INO:$INO halted
2. T:I can’t wait for “vertical integration” to start trending on Twitter, said no one to nobody. $T $TWX
3. ADRO:$ADRO halted
5. BIDU:Hearing Baidu $BIDU is gapping up on a early AM upgrade at OTR
7. AMTD:It’s like the AT&T-Time Warner deal for online brokers! Okay. Not exactly. But TD Ameritrade scooping up Scottrade for $4B. $AMTD
8. HLT:HNA buying 25% stake in Hilton $HLT for $26.25/share cash, $6.5B. Reduces Blackstone investment in HLT to 21%
9. KMB:$KMB Kimberly-Clark Q3 16 Earnings Results: -Adj EPS: $1.52 -Revenue: $4.59B
Trending News Headlines
1. Apple is sitting on ‘a powder keg of dramatically aging’ iPhones
Apple reports its September quarter earnings…
2. TD Ameritrade is buying Scottrade for $4 billion
The retail broker TD Ameritrade is buying the discount brokerage Scottrade for about $4 billion.
Technology News
Today’s Economic Calendar
8:30 Chicago Fed National Activity Index
9:00 Fed’s Dudley: “Evolving Structure of the U.S. Treasury Market”
9:05 Fed’s Bullard speech
9:45 PMI Manufacturing Index Flash
1:45 PM Fed’s Powell: “Future of the settlement process for Treasury market”
by Alpha | Oct 21, 2016 | Pre-Market
PRE-MARKET MOVERS
UPGRADES
4. CHK:$CHK upgraded to Neutral at Nomura, upgraded to Neutral at BankofAmerica
6. PM, RAI:Sept 15 Goldman downgraded $RAI & Upgrade $PM, Citi intiated $RAI at Buy w/ $57 PT. Now BAT is buying remaining RAI stake.
DOWNGRADES
2. PM, RAI:Sept 15 Goldman downgraded $RAI & Upgrade $PM, Citi intiated $RAI at Buy w/ $57 PT. Now BAT is buying remaining RAI stake.
EARNINGS
Trending Social Alerts
1. GE:$GE General Electric Q3 16 Earnings Results: -EPS: $0.32 -Revenue: $29.3B
2. MSFT:A 13-year ascent, then leveled off for 17 years. Here’s the full view of $MSFT since its 1986 IPO. Who’s got a cost…
3. MRK:$MRK’s KEYNOTE-045 Studying KEYTRUDA® in Advanced Bladder Cancer Meets Primary Endpoint and Stops Early
6. TWLO:Twilio prices secondary offering at $40. Remember it was a $70 “hot-IPO” three weeks ago? $TWLO
Trending News Headlines
1. Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Advanced Bladder Cancer (Urothelial Cancer) Meets Primary Endpoint and Stops Early
KEYTRUDA is the First Immunotherapy to Show Improved Overall Survival Compared With Chemotherapy in Urothelial Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the phase 3 KEYNOTE-045 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with previously treated advanced urothelial cancer, met the primary endpoint of overall survival (OS). In this trial, KEYTRUDA was superior compared to investigator choice chemotherapy. Based on a pre-specified interim analysis, an independent Data Monitoring Committee (DMC) has recommended that the trial be stopped early. “The results of KEYNOTE-045 represent a major breakthrough and will be welcome news for patients dealing with previously treated advanced urothelial cancer,” said Dr. Roger M. Perlmutter , president, Merck Research Laboratories . “We look forward to sharing the findings from this study with the medical community and with regulatory
2. No partner in sight, Twitter faces tough solo choices
The apparent lack of interest in Twitter Inc by potential suitors may force the social media company to consider a route anathema to aspiring tech startups: a major restructuring and cutting some its nearly 4,000 employees.
Technology News
Today’s Economic Calendar
10:15 Daniel Tarullo speech
1:00 PM Baker-Hughes Rig Coun
If you enjoy the content from SeekingOptions, please like our Facebook page and subscribe to our Youtube Channel
See you in the chat room
$BHI jumpy after reportedly in talks with $GE